Background: Quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma has become the standard of care in the management of HIV-infected patients. There are several commercially available assays that have been implemented for the detection of HIV-1 RNA in plasma. Here, the new Hologic Aptima® HIV-1 Quant Dx assay (Aptima HIV) was compared to the Roche COBAS® TaqMan® HIV-1 Test v2.0 for use with the High Pure System (HPS/CTM).
Methods: The performance characteristics of the assays were assessed using commercially available HIV reference panels, dilution of the WHO 3rd International HIV-1 RNA International Standard (WHO-IS) and plasma from clinical specimens. Assay performance was determined by linear regression, Deming correlation analysis and Bland-Altman analysis.
Results: Testing of HIV-1 reference panels revealed excellent agreement. The 61 clinical specimens quantified in both assays were linearly associated and strongly correlated.
Conclusions: The Aptima HIV assay offers performance comparable to that of the HPS/CTM assay and, as it is run on a fully automated platform, a significantly improved workflow.
This study was supported by Hologic Inc., San Diego, CA. We offer special thanks to the members of the Molecular Biology Department of the Laboratory Prof. Enders in Stuttgart, Germany for excellent technical assistance.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929–38.Search in Google Scholar
2. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946–54.Search in Google Scholar
3. O’Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997;126:939–45.Search in Google Scholar
4. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, et al., on behalf of the BHIVA Guidelines Subcommittee. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012;13:1–44.Search in Google Scholar
5. Website: Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: . Accessed 1 December, 2014.Search in Google Scholar
6. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. J Am Med Assoc 2012;308:387–402.Search in Google Scholar
7. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, Switzerland: WHO Press, 2013.Search in Google Scholar
8. Bourlet T, Signori-Schmuck A, Roche L, Icard V, Saoudin H, Trabaud MA, et al. HIV-1 load comparison using four commercial real-time assays. J Clin Microbiol 2011;49:292–7.Search in Google Scholar
9. Church D, Gregson D, Lloyd T, Klein M, Beckthold B, Laupland K, et al. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2 and Versant assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol 2011;49:118–24.Search in Google Scholar
10. Garcia-Diaz A, Clewley GS, Booth CL, Labett W, McAllister N, Geretti AM. Comparative evaluation of the performance of the Abbott Real-Time Human Immunodeficiency Virus type 1 (HIV-1) assay for the measurement of HIV-1 plasma viral load following automated specimen preparation. J Clin Microbiol 2006;44:1788–91.Search in Google Scholar
11. Garcia-Diaz A, Labbett W, Clewley GS, Guerrero-Ramos A, Geretti AM. Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma. J Clin Virol 2013;57:66–9.Search in Google Scholar
12. Schutten M, Peters D, Back NK, Beld M, Beuselinck K, Foulongne V, et al. Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2007;45: 1712–7.Search in Google Scholar
13. Perrin L, Pawlotsky JM, Bouvier-Alias M, Sarrazin C, Zeuzem S, Colucci G. Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol 2006;44:4371–5.Search in Google Scholar
14. Coombs R, Bremer J, Sanchez J, La Rosa A, Fernandes H, Ganoza C, et al. Clinical performance evaluation of the COBAS TaqMan HIV-1 Test for use with the High Pure System v2.0 (HPS/CTM HIV v2) using manual specimen extraction, compared to the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0 (CAP/CTM HIV Test v2) using automated specimen extraction. J Int AIDS Soc 2012;15(Suppl 3):THPE060.Search in Google Scholar
15. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425–33.Search in Google Scholar
16. Wiesmann F, Naeth G, Sarrazin C, Berger A, Kaiser R, Ehret R, et al. Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol 2015;204:515–25.Search in Google Scholar
17. Pyne MT, Vest L, Clement J, Lee J, Rosvall JR, Luk K, et al. Comparison of three Roche hepatitis B virus viral load assay formats. J Clin Microbiol 2012;50:2337–42.Search in Google Scholar
18. Hill CS. Molecular diagnostic testing for infectious diseases using TMA technology. Expert Rev Mol Diagn 2001;1:445–55.Search in Google Scholar
19. Janssens W, Heyndrickx L, Fransen K, Motte J, Peeters M, Nkengasong JN, et al. Genetic and phylogenetic analysis of env subtypes G and H in central Africa. Aids Res Hum Retroviruses 1994;10:877–9.Search in Google Scholar
20. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. J Virol Methods 2011;173:399–402.Search in Google Scholar
21. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Piérard D, et al. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis 2012;12:100–5.Search in Google Scholar
22. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, et al. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J Clin Virol 2010;49:249–53.Search in Google Scholar
©2016 by De Gruyter